The drug doesn't care what you're craving—it just turns down the craving signal
A large observational study from the University of Texas has surfaced an unexpected possibility: medications developed to regulate blood sugar and appetite may also quiet the brain's hunger for something far more dangerous. Analyzing data from more than 142,000 patients, researchers found that those taking GLP-1 drugs like Ozempic showed dramatically lower rates of alcohol, opioid, nicotine, and cocaine use disorders — differences so large they suggest these medications may be touching something fundamental in how the brain generates craving. The finding does not yet prove causation, but it opens a serious question about whether a metabolic drug might one day belong in the addiction treatment toolkit.
- Reductions of 68 to 75 percent in substance use disorder rates across four different addictive substances are not statistical noise — they demand explanation.
- The leading hypothesis points to dopamine: GLP-1 drugs may be dampening the same neural reward circuits that drive compulsive desire for food, alcohol, opioids, and cocaine alike.
- Researchers are urging caution, warning that observational data cannot rule out the possibility that GLP-1 users are simply healthier, more motivated, or better-resourced than comparison patients.
- No clinician should prescribe Ozempic for addiction based on this study alone — randomized controlled trials remain the necessary next step before any such recommendation could be made.
- The team is already planning prospective studies to follow patients as they begin GLP-1 therapy, watching in real time for shifts in substance use behavior and mental health outcomes.
Researchers at the University of Texas at El Paso set out to analyze health data and found something they hadn't anticipated: patients taking GLP-1 medications appeared far less likely to develop addictions to alcohol, opioids, nicotine, and cocaine. The study drew on more than 142,000 patients with type 2 diabetes or obesity — about 20,000 of them on GLP-1 drugs like Ozempic — sourced from the NIH's All of Us Research program, one of the country's most expansive health databases.
The differences between GLP-1 users and non-users were striking. Those on the medications showed 74 percent lower odds of alcohol use disorder, 69 percent lower odds for opioid addiction, 68 percent for nicotine dependence, and 75 percent for cocaine use disorder. Lead researchers Tadesse Abegaz and Gabriel Frietze, publishing in Frontiers in Psychiatry, believe the mechanism may lie in how GLP-1 drugs interact with dopamine signaling and the brain's reward pathways — systems that govern craving not just for food, but for substances of all kinds.
The team is careful about what the findings actually prove. Because the study is observational, it cannot establish that GLP-1 medications directly prevent addiction. People who take these drugs may differ from non-users in ways that independently reduce their risk — better healthcare access, stronger health motivation, or other unmeasured factors. Frietze was explicit that prescribing GLP-1s for addiction treatment cannot be justified on this evidence alone.
What comes next is a prospective phase: following patients as they begin GLP-1 therapy and tracking whether substance use behaviors shift over time. Abegaz frames the current work as exploratory groundwork — a door opened, not a conclusion reached. Whether these drugs ultimately find a place in addiction medicine depends on whether their effects on the brain's reward circuitry survive the rigors of controlled trials.
Researchers at the University of Texas at El Paso have found something unexpected in the data: people taking GLP-1 medications—the same drugs prescribed for weight loss and diabetes management—appear far less likely to develop addictions to alcohol, opioids, nicotine, and cocaine. The discovery emerged from a study of more than 142,000 patients with type 2 diabetes or obesity, roughly 20,000 of whom were taking GLP-1 drugs like Ozempic. When the team compared substance use disorder rates between those on the medications and similar patients who were not, the differences were striking.
The numbers tell a clear story. People using GLP-1 medications had 74 percent lower odds of developing an alcohol use disorder, 69 percent lower odds for opioid addiction, 68 percent lower odds for nicotine dependence, and 75 percent lower odds for cocaine use disorder. These are not marginal differences. They suggest something fundamental may be happening in the brain when these medications are at work. The lead researchers, Tadesse Abegaz and Gabriel Frietze of UTEP's School of Pharmacy, published their findings in Frontiers in Psychiatry after analyzing data from the National Institutes of Health's All of Us Research program, one of the nation's largest and most diverse health databases.
The mechanism behind the association points to how GLP-1 drugs interact with the brain's reward system. These medications were originally designed to regulate appetite and blood sugar, but emerging evidence suggests they influence dopamine signaling and other neural pathways that drive cravings—not just for food, but for other substances as well. Abegaz explained that the findings indicate GLP-1s may affect brain regions involved in reward and craving, which could account for the lower addiction rates his team observed. The implication is that by dampening the neural circuits that generate compulsive desire, these drugs might inadvertently protect against substance abuse.
Yet the researchers are careful not to overstate what they have found. The study is observational, meaning it shows an association but cannot prove that GLP-1 medications actually prevent addiction. People taking these drugs may differ from non-users in ways that independently lower their addiction risk—better access to care, higher motivation to manage their health, or other unmeasured factors. Frietze was explicit: the team does not recommend prescribing GLP-1s for addiction treatment based on this evidence alone. Randomized clinical trials, the gold standard in medical research, would be needed before such a step could be justified.
Still, the researchers see promise in the findings and plan to pursue the question further. Their next phase will involve prospective studies that follow patients starting GLP-1 therapy over time, tracking whether substance use behaviors actually change after treatment begins and whether those changes correlate with improvements in mental health and quality of life. Abegaz framed the work as exploratory groundwork that might eventually inform whether GLP-1 medications could become part of a broader addiction treatment toolkit. For now, the study opens a door—suggesting that a drug class developed to manage metabolic disease may have unexpected effects on the brain's deepest reward pathways. What happens next depends on whether those effects hold up under the scrutiny of controlled trials.
Citas Notables
These medications appear to affect brain pathways involved in reward and craving, which could help explain the lower rates of substance use disorders observed in our study.— Tadesse Abegaz, lead researcher
We do not support prescribing these medications for addiction treatment at this time. Randomized clinical trials are needed before GLP-1 medications can be recommended for treating addiction.— Gabriel Frietze, co-researcher
La Conversación del Hearth Otra perspectiva de la historia
Why would a weight loss drug affect addiction risk at all? They seem unrelated.
They're not as separate as they seem. Both appetite and addiction involve the same reward circuitry in the brain—dopamine, craving, the drive to seek something. GLP-1s were designed to quiet food cravings, but that same quieting appears to work on other cravings too.
So you're saying the drug doesn't care what you're craving—it just turns down the craving signal?
Essentially, yes. The researchers think GLP-1s influence dopamine pathways that generate desire itself. If you dampen that system, you dampen all kinds of wanting.
But the study doesn't prove the drug causes the lower addiction rates, right?
Correct. It's observational. People on GLP-1s might be more health-conscious to begin with, or have better support systems. The association is real, but causation is still unknown.
What would it take to actually know?
Randomized trials where some people get the drug and others get a placebo, and you follow them over time to see if substance use actually changes. That's the next step the researchers want to take.
And if those trials work out?
Then you might eventually see GLP-1s prescribed not just for weight and diabetes, but as part of addiction treatment. But we're years away from that.